{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:46:56Z","timestamp":1774568816116,"version":"3.50.1"},"reference-count":33,"publisher":"Bentham Science Publishers Ltd.","issue":"11","funder":[{"DOI":"10.13039\/501100004681","name":"Higher Education Commission, Pakistan","doi-asserted-by":"publisher","award":["106-2333-PS6-138"],"award-info":[{"award-number":["106-2333-PS6-138"]}],"id":[{"id":"10.13039\/501100004681","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2019,12,23]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Intestinal \u03b2-glucuronidase enzyme has a significant importance in colorectal\ncarcinogenesis. Specific inhibition of the enzyme helps prevent immune reactivation of the glucuronide-\ncarcinogens, thus protecting the intestine from ROS (Reactive Oxidative Species) mediatedcarcinogenesis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Advancement in In-silico based techniques has provided a broad range of studies to\ncarry out the drug design and development process smoothly using SwissADME and BOILED-Egg\ntools.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> In our designed case study, we used SwissADME and BOILED-Egg predictive computational\ntools to estimate the physicochemical, human pharmacokinetics, drug-likeness, medicinal\nchemistry properties and membrane permeability characteristics of our recently In-vitro evaluated\nnovel \u03b2-Glucuronidase inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Out of the eleven screened potent inhibitors, compound (8) exhibited excellent bioavailability\nradar against the six molecular descriptors, good (ADME) Absorption, Distribution, Metabolism\nand Excretion along with P-glycoprotein, CYP450 isozymes and membranes permeability profile.\nOn the basis of these factual observations, it is to be predicted that compound (8) can achieve in-vivo\nexperimental clearance efficiently, Therefore, in the future, it can be a drug in the market to treat\nvarious disorders associated with the overexpression of \u03b2-Glucuronidase enzyme such as various\ntypes of cancer, particularly hormone-dependent cancer such as (breast, prostate, and colon cancer).\nMoreover, other compounds (1-7, &amp; 9-11), have also shown good predictive pharmacokinetics, medicinal\nchemistry, BBB and HIA membranes permeability profiles with slight lead optimization to\nobtain improved results.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In consequence, in-silico based studies are considered to provide robustness for a rational\ndrug design and development approach to avoid the possibility of failures of drug candidates\nin the later stages of drug development phases. The results of this study effectively reveal the possible\nattributes of potent \u03b2-Glucuronidase inhibitors, for further experimental evaluation.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009619666190320102238","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T03:32:56Z","timestamp":1553139176000},"page":"906-918","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in In-Silico based Predictive In-Vivo Profiling of Novel Potent \u03b2-Glucuronidase Inhibitors"],"prefix":"10.2174","volume":"19","author":[{"given":"Maria","family":"Yousuf","sequence":"first","affiliation":[{"name":"Department of Bioinformatics, Dow College of Biotechnology, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1875397301105010013","volume":"5","author":"Ahmad S.","year":"2011","unstructured":"Ahmad S.; Hughes M.A.; Lane K.T.; Redinbo M.R.; Yeh L.A.; Scott J.E.; High throughput assay for discovery of bacterial \u03b2-glucuronidase inhibitors. Curr Chem Genomics 2011,5,13-20","journal-title":"Curr Chem Genomics"},{"key":"ref=2","author":"Di Li","year":"2013","unstructured":"Di Li; Feng Bo; Theunis C.;  Scott Obach A Perspective on the\nPrediction of Drug Pharmacokinetics and Disposition in Drug Research\nand Development Drug Metab Dispos 41, p. 1975-\n1993.2013","journal-title":"Scott Obach A Perspective on the\nPrediction of Drug Pharmacokinetics and Disposition in Drug Research\nand Development Drug Metab Dispos"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1021\/ci200311w","volume":"51","author":"Hongmao S.","year":"2011","unstructured":"Hongmao S.; Henrike V.; Menghang X.; Christopher P.; Austin, and ruili huang predictive models for cytochrome p450 isozymes based on quantitative high throughput screening data. Chem Inf Model 2011,51(10),2474-2481","journal-title":"Chem Inf Model"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200502","author":"Yousuf M.","year":"2018","unstructured":"Yousuf M.; Shaikh N.N.; Zaheer ul-Haq","journal-title":"PLoS One"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"34057","DOI":"10.1074\/jbc.273.51.34057","volume":"273","author":"Wong A.W.","year":"1998","unstructured":"Wong A.W.; He S.; Grubb J.H.J.; Sly W.S.; Withers S.G.; Identification of Glu-540 as the catalytic nucleophile of human beta-glucuronidase using electrospray mass spectrometry. J Biol Chem 1998,273(51),34057-34062","journal-title":"J Biol Chem"},{"key":"ref=6","first-page":"178","volume":"21","author":"Walaszek Z.","year":"1997","unstructured":"Walaszek Z.; Szemraj J.; Narog M.; Adams A.K.; Kilgore J.; Sherman U.; Hanausek M.; Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. Cancer Detect Prev 1997,21(2),178-190","journal-title":"Cancer Detect Prev"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","year":"2017","unstructured":"Antoine Daina1, Olivier Michielin1,2,3","journal-title":"Sci Rep"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/cmdc.201600182","volume":"11","author":"Daina A.","year":"2016","unstructured":"Daina A.; Zoete V.; BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016,11(11),1117-1121","journal-title":"ChemMedChem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrd4609","volume":"14","author":"Waring M.J.","year":"2015","unstructured":"Waring M.J.; Arrowsmith J.; Leach A.R.; Leeson P.D.; Mandrell S.; Owen R.M.; Pairaudeau G.; Pennie W.D.; Pickett S.D.; Wang J.; Wallace O.; Weir A.; An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov 2015,14(7),475-486","journal-title":"Nat Rev Drug Discov"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.drudis.2009.07.010","volume":"14","author":"Bansal T.","year":"2009","unstructured":"Bansal T.; Akhtar N.; Jaggi M.; Khar R.K.; Talegaonkar S.; Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today 2009,14(21-22),1067-1074","journal-title":"Drug Discov Today"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.drudis.2007.07.022","volume":"12","author":"Aszalos A.","year":"2007","unstructured":"Aszalos A.; Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1) I. Preclinical aspects. Drug Discov Today 2007,12(19-20),833-837","journal-title":"Drug Discov Today"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1517\/17425255.2014.876006","volume":"10","author":"Di L.","year":"2014","unstructured":"Di L.; The role of drug metabolizing enzymes in clearance. Expert Opin Drug Metab Toxicol 2014,10(3),379-393","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1081\/DMR-120001387","volume":"34","author":"Hollenberg P.F.","year":"2002","unstructured":"Hollenberg P.F.; Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 2002,34(1-2),17-35","journal-title":"Drug Metab Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/0091270007312153","volume":"48","author":"Huang S-M.","year":"2008","unstructured":"Huang S-M.; Strong J.M.; Zhang L.; Reynolds K.S.; Nallani S.; Temple R.; Abraham S.; Habet S.A.; Baweja R.K.; Burckart G.J.; Chung S.; Colangelo P.; Frucht D.; Green M.D.; Hepp P.; Karnaukhova E.; Ko H.S.; Lee J.I.; Marroum P.J.; Norden J.M.; Qiu W.; Rahman A.; Sobel S.; Stifano T.; Thummel K.; Wei X.X.; Yasuda S.; Zheng J.H.; Zhao H.; Lesko L.J.; New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008,48(6),662-670","journal-title":"J Clin Pharmacol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd4581","volume":"14","author":"Kirchmair J.","year":"2015","unstructured":"Kirchmair J.; G\u00f6ller A.H.; Lang D.; Kunze J.; Testa B.; Wilson I.D.; Glen R.C.; Schneider G.; Predicting drug metabolism: experiment and\/or computation? Nat Rev Drug Discov 2015,14(6),387-404","journal-title":"Nat Rev Drug Discov"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nbt.1581","volume":"27","author":"Veith H.","year":"2009","unstructured":"Veith H.; Southall N.; Huang R.; James T.; Fayne D.; Artemenko N.; Shen M.; Inglese J.; Austin C.P.; Lloyd D.G.; Auld D.S.; Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat Biotechnol 2009,27(11),1050-1055","journal-title":"Nat Biotechnol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1023\/A:1015810312465","volume":"9","author":"Potts R.O.","year":"1992","unstructured":"Potts R.O.; Guy R.H.; Predicting skin permeability. Pharm Res 1992,9(5),663-669","journal-title":"Pharm Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/cc9800071","volume":"1","author":"Ghose A.K.","year":"1999","unstructured":"Ghose A.K.; Viswanadhan V.N.; Wendoloski J.J.; A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999,1(1),55-68","journal-title":"J Comb Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1021\/jm020017n","volume":"45","author":"Veber D.F.","year":"2002","unstructured":"Veber D.F.; Johnson S.R.; Cheng H.Y.; Smith B.R.; Ward K.W.; Kopple K.D.; Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002,45(12),2615-2623","journal-title":"J Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1021\/jm000292e","volume":"43","author":"Egan W.J.","year":"2000","unstructured":"Egan W.J.; Merz K.M.; Baldwin J.J.; Prediction of drug absorption using multivariate statistics. J Med Chem 2000,43(21),3867-3877","journal-title":"J Med Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1021\/jm015507e","volume":"44","author":"Muegge I.","year":"2001","unstructured":"Muegge I.; Heald S.L.; Brittelli D.; Simple selection criteria for drug-like chemical matter. J Med Chem 2001,44(12),1841-1846","journal-title":"J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"Lipinski C.A.","year":"2001","unstructured":"Lipinski C.A.; Lombardo F.; Dominy B.W.; Feeney P.J.; Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001,46(1-3),3-26","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrd1156","volume":"2","author":"Kubinyi H.","year":"2003","unstructured":"Kubinyi H.; Drug research: myths, hype and reality. Nat Rev Drug Discov 2003,2(8),665-668","journal-title":"Nat Rev Drug Discov"},{"key":"ref=24","doi-asserted-by":"publisher","DOI":"10.1002\/9783527614998","author":"Pliska V.","unstructured":"Pliska V.; Testa, B.; van de Waterbeemd, H. Lipophilicity in\nDrug Action and Toxicology 1\u20136 Wiley-VCH Verlag GmbH1996","journal-title":"Lipophilicity in\nDrug Action and Toxicology 1\u20136"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1517\/17460441.2012.714363","volume":"7","author":"Arnott J.A.","year":"2012","unstructured":"Arnott J.A.; Planey S.L.; The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 2012,7(10),863-875","journal-title":"Expert Opin Drug Discov"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jps.21494","volume":"98","author":"Mannhold R.","year":"2009","unstructured":"Mannhold R.; Poda G.I.; Ostermann C.; Tetko I.V.; Calculation of molecular lipophilicity: State-of-the-art and comparison of log P methods on more than 96,000 compounds. J Pharm Sci 2009,98(3),861-893","journal-title":"J Pharm Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1021\/ci700257y","volume":"47","author":"Cheng T.","year":"2007","unstructured":"Cheng T.; Zhao Y.; Li X.; Lin F.; Xu Y.; Zhang X.; Li Y.; Wang R.; Lai L.; Computation of octanol-water partition coefficients by guiding an additive model with knowledge. J Chem Inf Model 2007,47(6),2140-2148","journal-title":"J Chem Inf Model"},{"key":"ref=28","first-page":"868","volume":"39","author":"Wildman S.A.","year":"1999","unstructured":"Wildman S.A.; Crippen G.M.; Prediction of physicochemical parameters by atomic contributions. J Chem Inf Model 1999,39,868-873","journal-title":"J Chem Inf Model"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1248\/cpb.40.127","volume":"40","author":"Moriguchi I.","year":"1992","unstructured":"Moriguchi I.; Shuichi H.; Liu Q.; Nakagome I.; Matsushita Y.; Simple method of calculating octanol\/water partition coefficient. Chem Pharm Bull (Tokyo) 1992,40,127-130","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1248\/cpb.42.976","volume":"42","author":"Moriguchi I.","year":"1994","unstructured":"Moriguchi I.; Shuichi H.; Nakagome I.; Hirano H.; Comparison of reliability of log P values for Drugs calculated by several methods. Chem Pharm Bull (Tokyo) 1994,42,976-978","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1021\/ci200387c","volume":"52","author":"Ali J.","year":"2012","unstructured":"Ali J.; Camilleri P.; Brown M.B.; Hutt A.J.; Kirton S.B.; Revisiting the general solubility equation: in silico prediction of aqueous solubility incorporating the effect of topographical polar surface area. J Chem Inf Model 2012,52(2),420-428","journal-title":"J Chem Inf Model"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1021\/ci034243x","volume":"44","author":"John S.","year":"2004","unstructured":"John S.; Delaney, ESOL: Estimating aqueous solubility directly from molecular structure. J Chem Inf Comput Sci 2004,44,1000-1005","journal-title":"J Chem Inf Comput Sci"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2017.194","volume":"17","author":"Shih H.P.","year":"2018","unstructured":"Shih H.P.; Zhang X.; Aronov A.M.; Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nat Rev Drug Discov 2018,17(1),19-33","journal-title":"Nat Rev Drug Discov"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T10:58:17Z","timestamp":1579863497000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170854\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,12,23]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009619666190320102238","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}